Paper36069059
Proteolytically generated soluble Tweak Receptor Fn14 is a blood biomarker for γ-secretase activity.
Güner G and 17 others. EMBO Mol Med, 2022. Cited by 11 papers, by iCite.
Cite this record
ConductScience Library. Proteolytically generated soluble Tweak Receptor Fn14 is a blood biomarker for γ-secretase activity. Papers, record 36069059. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36069059
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Amyloid Precursor Protein Secretases | Major topic |
| Receptors, Chimeric Antigen | Major topic |
| Animals | |
| Biomarkers | |
| Cytokine TWEAK | |
| Humans | |
| Ligands | |
| Mice | |
| Receptors, Cell Surface | |
| Receptors, Tumor Necrosis Factor | |
| TWEAK Receptor | |
| Tumor Necrosis Factor-alpha |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| P01 CA018029 | NCI NIH HHS | United States | P01CA018029 | PubMed | NIH RePORTER |
| R01 CA114536 | NCI NIH HHS | United States | R01CA114536 | PubMed | NIH RePORTER |
References84
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 29190188 | Biomeasures and mechanistic modeling highlight PK/PD risks for a monoclonal antibody targeting Fn14 in kidney disease. | MAbs | 2018 | https://conductscience.org/library/papers/29190188 | PubMed |
| 2 | 35032596 | Comparative transcriptome analysis of human and murine choroidal neovascularization identifies fibroblast growth factor inducible-14 as phylogenetically conserved mediator of neovascular age-related macular degeneration. | Biochim Biophys Acta Mol Basis Dis | 2022 | https://conductscience.org/library/papers/35032596 | PubMed |
| 3 | 34475100 | Imaging of Cancer γ-Secretase Activity Using an Inhibitor-Based PET Probe. | Clin Cancer Res | 2021 | https://conductscience.org/library/papers/34475100 | PubMed |
| 4 | 31580829 | A single molecule assay for ultrasensitive detection of Fn14 in human serum. | Anal Biochem | 2019 | https://conductscience.org/library/papers/31580829 | PubMed |
| 5 | 31998833 | Decreased nonspecific adhesivity, receptor-targeted therapeutic nanoparticles for primary and metastatic breast cancer. | Sci Adv | 2020 | https://conductscience.org/library/papers/31998833 | PubMed |
| 6 | 11145990 | Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. | J Neurochem | 2001 | https://conductscience.org/library/papers/11145990 | PubMed |
| 7 | 10751351 | The Fn14 immediate-early response gene is induced during liver regeneration and highly expressed in both human and murine hepatocellular carcinomas. | Am J Pathol | 2000 | https://conductscience.org/library/papers/10751351 | PubMed |
| 8 | 26300004 | The TWEAK receptor Fn14 is a potential cell surface portal for targeted delivery of glioblastoma therapeutics. | Oncogene | 2016 | https://conductscience.org/library/papers/26300004 | PubMed |
| 9 | 34543184 | Synaptotagmin 7 is targeted to the axonal plasma membrane through γ-secretase processing to promote synaptic vesicle docking in mouse hippocampal neurons. | Elife | 2021 | https://conductscience.org/library/papers/34543184 | PubMed |
| 10 | 27293189 | Restricted Location of PSEN2/γ-Secretase Determines Substrate Specificity and Generates an Intracellular Aβ Pool. | Cell | 2016 | https://conductscience.org/library/papers/27293189 | PubMed |
| 11 | 21697654 | Development of an Fn14 agonistic antibody as an anti-tumor agent. | MAbs | 2011 | https://conductscience.org/library/papers/21697654 | PubMed |
| 12 | 14638693 | Evidence for a critical role of the tumor necrosis factor alpha convertase (TACE) in ectodomain shedding of the p75 neurotrophin receptor (p75NTR). | J Biol Chem | 2004 | https://conductscience.org/library/papers/14638693 | PubMed |
| 13 | 23190886 | The TWEAK receptor Fn14 is a therapeutic target in melanoma: immunotoxins targeting Fn14 receptor for malignant melanoma treatment. | J Invest Dermatol | 2013 | https://conductscience.org/library/papers/23190886 | PubMed |
| 14 | 31262047 | Comparative Transcriptomic Analysis of Temozolomide Resistant Primary GBM Stem-Like Cells and Recurrent GBM Identifies Up-Regulation of the Carbonic Anhydrase CA2 Gene as Resistance Factor. | Cancers (Basel) | 2019 | https://conductscience.org/library/papers/31262047 | PubMed |
| 15 | 12679784 | Reconstitution of gamma-secretase activity. | Nat Cell Biol | 2003 | https://conductscience.org/library/papers/12679784 | PubMed |
| 16 | 32616437 | The substrate repertoire of γ-secretase/presenilin. | Semin Cell Dev Biol | 2020 | https://conductscience.org/library/papers/32616437 | PubMed |
| 17 | 19828817 | gamma-Secretase: successive tripeptide and tetrapeptide release from the transmembrane domain of beta-carboxyl terminal fragment. | J Neurosci | 2009 | https://conductscience.org/library/papers/19828817 | PubMed |
| 18 | 24391646 | TWEAK/Fn14 Axis-Targeted Therapeutics: Moving Basic Science Discoveries to the Clinic. | Front Immunol | 2013 | https://conductscience.org/library/papers/24391646 | PubMed |
| 19 | 29459438 | Non-cell-autonomous function of DR6 in Schwann cell proliferation. | EMBO J | 2018 | https://conductscience.org/library/papers/29459438 | PubMed |
| 20 | 27059953 | Presenilin 1 and Presenilin 2 Target γ-Secretase Complexes to Distinct Cellular Compartments. | J Biol Chem | 2016 | https://conductscience.org/library/papers/27059953 | PubMed |
Cited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 11 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41358571 | Proteomic and Transcriptomic Signatures of Poor Asthma Symptom Control in the U-BIOPRED Cohort. | Allergy | 2026 | https://conductscience.org/library/papers/41358571 | PubMed |
| 40593564 | Charting γ-secretase substrates by explainable AI. | Nat Commun | 2025 | https://conductscience.org/library/papers/40593564 | PubMed |
| 38980441 | Cleavage site-directed antibodies reveal the prion protein in humans is shed by ADAM10 at Y226 and associates with misfolded protein deposits in neurodegenerative diseases. | Acta Neuropathol | 2024 | https://conductscience.org/library/papers/38980441 | PubMed |
| 36069059 | Proteolytically generated soluble Tweak Receptor Fn14 is a blood biomarker for γ-secretase activity. | EMBO Mol Med | 2022 | https://conductscience.org/library/papers/36069059 | PubMed |
Genes22
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36069059
GET https://conductscience.org/api/papers/v1/36069059/references?page=2